Therapeutic trials with levamisole and other agents in NZB/W mice

Area of Science:

• Immunology
• Pharmacology
• Autoimmune Diseases

Background:

• NZB/W mice spontaneously develop a lupus-like autoimmune disease.
• Understanding therapeutic interventions for autoimmune diseases is crucial.

Purpose of the Study:

• To evaluate the efficacy of levamisole, ribovirin, and cyclophosphamide in preventing spontaneous autoimmune disease in NZB/W mice.
• To assess the impact of these drugs on mortality, antinuclear antibodies, and proteinuria.

Main Methods:

• NZB/W mice were treated with levamisole, ribovirin, and cyclophosphamide.
• Disease progression markers including mortality, antinuclear antibodies, and proteinuria were monitored.
• A single-stranded DNA linked to IgG was also tested for its effect.

Main Results:

• Levamisole, ribovirin, and cyclophosphamide significantly delayed mortality and postponed the onset of antinuclear antibodies and proteinuria.
• Single-stranded DNA linked to IgG showed no demonstrable effect in preventing the disease.
• The therapeutic effects observed in murine lupus models require cautious interpretation for human application.

Conclusions:

• Levamisole and ribovirin demonstrate potential as therapeutic agents for autoimmune diseases.
• Given their current use in humans, further clinical studies investigating levamisole and ribovirin are warranted.
• Cyclophosphamide also showed efficacy, but levamisole and ribovirin may offer alternative therapeutic strategies.